Intensity Therapeutics Q2 2024 Adj EPS $(0.36) Misses $(0.32) Estimate
Portfolio Pulse from Benzinga Newsdesk
Intensity Therapeutics (NASDAQ:INTS) reported a Q2 2024 adjusted EPS of $(0.36), missing the analyst consensus estimate of $(0.32) by 12.5%.
August 08, 2024 | 9:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intensity Therapeutics reported a Q2 2024 adjusted EPS of $(0.36), missing the analyst consensus estimate of $(0.32) by 12.5%. This earnings miss could negatively impact the stock price in the short term.
The earnings miss of 12.5% below the analyst consensus estimate is likely to be viewed negatively by investors, potentially leading to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100